HilleVax is a biopharmaceutical company focused on the development and commercialization of novel vaccines. Their initial program, HIL-214, is a virus-like particle (VLP) based vaccine candidate in development for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection.

Biotechnology

Hillevax

Rob Hershberg

Qi Li

Wendy T.

Anju Chatterji

Tara Raab

Tomoe Felder

Shannon Harris

Shane Maltbie

Ozzie Berger

Holger Koch

Christopher Aakre, PhD

Astrid Borkowski

Paul Bavier

Aditya Kohli

The Leadership Team at HilleVax drives the strategic direction of the company, overseeing the development and commercialization of its vaccine candidates, including HIL-214 for norovirus prevention. Comprising key executives such as the CEO, COO, and Chief Medical and Technology Officers, the team collaborates on research initiatives, regulatory compliance, and operational efficiencies to ensure successful product delivery and market impact.

Leadership Team

Directors Team

Research and Development

Leadership Team

About

Team members

Other teams at Hillevax

Directors Team

Research and Development